Novavax updated COVID-19 vaccine receives EUA in Republic of Korea

Novavax’s partner, SK bioscience, announced that Novavax’s updated COVID-19 vaccine has received Emergency Use Authorization, or EUA, from the Ministry of Food and Drug Safety in the Republic of Korea. “Doses are available in market for use this vaccination season. In South Korea, SK bioscience and Novavax have a licensing agreement where SK bioscience has exclusive commercial rights to Novavax’s updated COVID-19 vaccine. Novavax’s updated COVID-19 vaccine is also authorized in the U.S., the European Union and by the World Health Organization, and is under review in other markets,” Novavax stated.